Animal studies have shown that GM-CSF combined with immune checkpoint inhibitors can improve the effectiveness of PD-1/PD-L1 inhibitors by improving antigen presentation and attracting T cells to infiltrate the tumor microenvironment (56, 57). Here, CD274 is linked to neoplasm.